Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.
Authors:
Journal: Endocrine
Publication Type: Journal Article
Date: 2004
DOI: 10.1385/ENDO:23:2-3:125
ID: 15146090
Abstract
Erectile dysfunction (ED) is commonly associated with risk factors for cardiovascular disease, including diabetes. The prevalence of ED in diabetic patients is high--about 75% of diabetic men 60 yr of age or older had ED in one study. Endothelial dysfunction, accelerated atherosclerosis, and diabetic neuropathy likely contribute to ED in diabetics. As silent ischemia is common in the diabetic patient, and diabetes is now often thought of as a coronary heart disease risk equivalent, diabetic men seeking therapy for ED may be considered candidates for exercise stress testing. Phosphodiesterase 5 (PDE5) inhibitors improve erectile function in diabetic men with ED; however, efficacy rates may be somewhat lower than in nondiabetic men. Studies to date have suggested that PDE5 inhibitors per se do not cause an increase in myocardial infarction rates in men being treated for ED.
Chemical List
- Phosphodiesterase Inhibitors|||3',5'-Cyclic-GMP Phosphodiesterases|||Cyclic Nucleotide Phosphodiesterases, Type 5|||PDE5A protein, human
Reference List
- JAMA. 1999 Feb 3;281(5):421-6|||Am J Cardiol. 1999 Feb 15;83(4):576-82, A7|||Am J Cardiol. 2000 Jul 20;86(2A):51F-56F|||Am J Hypertens. 2001 Jan;14(1):70-3|||Diabetes Care. 2002 Aug;25(8):1458-63|||Am J Cardiol. 2002 Jun 1;89(11):1331-4|||Diabetologia. 1980 Apr;18(4):279-83|||JAMA. 1993 Jul 7;270(1):83-90|||Singapore Med J. 2002 Aug;43(8):387-90|||J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12|||N Engl J Med. 2000 Jun 1;342(22):1622-6|||Diabetes Care. 2002 Aug;25(8):1336-9|||Diabetes Care. 2002 Feb;25(2):284-91|||JAMA. 2002 Feb 13;287(6):719-25|||Diabetologia. 2001 Oct;44(10):1296-301|||Am J Cardiol. 2000 Jul 15;86(2):175-81|||Int J Impot Res. 2002 Dec;14(6):466-71|||Urology. 2002 Sep;60(2 Suppl 2):67-90|||JAMA. 1996 May 8;275(18):1405-9|||Diabetes Educ. 1999 Jan-Feb;25(1):79-80, 83-4, 87 passim|||J Am Coll Cardiol. 2000 Sep;36(3):845-51|||Hosp Med. 1999 Sep;60(9):638-44|||J Urol. 1994 Jan;151(1):54-61|||Diabetologia. 2001 Sep;44(9):1155-60|||J Urol. 2001 Oct;166(4):1368-71|||JAMA. 2001 May 16;285(19):2486-97|||Diabetes Care. 1996 Feb;19(2):135-41|||BJU Int. 2001 Jul;88(1):68-71